Fate Therapeutics Inc FATE.OQ FATE.O is expected to show a fall in quarterly revenue when it reports results on November 10 (estimated) for the period ending September 30 2025
The San Diego California-based company is expected to report a 50.1% decrease in revenue to $1.535 million from $3.07 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
LSEG's mean analyst estimate for Fate Therapeutics Inc is for a loss of 29 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Fate Therapeutics Inc is $4.50, about 76.9% above its last closing price of $1.04
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.34 | -0.34 | -0.29 | Beat | 15.3 |
Mar. 31 2025 | -0.38 | -0.38 | -0.32 | Beat | 16.4 |
Dec. 31 2024 | -0.43 | -0.43 | -0.44 | Missed | -1.7 |
Sep. 30 2024 | -0.41 | -0.43 | -0.40 | Beat | 7.5 |
Jun. 30 2024 | -0.47 | -0.48 | -0.33 | Beat | 30.6 |
Mar. 31 2024 | -0.48 | -0.49 | -0.47 | Beat | 3.8 |
Dec. 31 2023 | -0.53 | -0.52 | -0.45 | Beat | 13.9 |
Sep. 30 2023 | -0.56 | -0.57 | -0.46 | Beat | 19.3 |
This summary was machine generated November 7 at 13:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)